AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

Biotec Pharmacon share price down 80%.

Chemical Business Newsbase

| November 23, 2009 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. (Hide copyright information)Copyright

Biotec Pharmacon's share price fell by 80% after it was announced that two Phase III clinical studies with SBG had failed to deliver positive results. The company has dropped the …

Related articles from newspapers, magazines, journals, and more
Positive preclinical results for Biotec Pharmacon diabetes treatment.
News wire article from: Chemical Business Newsbase September 20, 2010 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily